Download PDF
Thromb Haemost 1992; 68(03): 273-277
DOI: 10.1055/s-0038-1656364
Original Article
Schattauer GmbH Stuttgart

A Rapid Monoclonal Antibody-Based Enzyme Immunoassay (EIA) for the Quantitative Determination of Soluble Fibrin in Plasma

W Nieuwenhuizen
The IVVO-TNO, Gaubius Laboratory, Leiden, The Netherlands
,
E Hoegee-De Nobel
The IVVO-TNO, Gaubius Laboratory, Leiden, The Netherlands
,
R Laterveer
The IVVO-TNO, Gaubius Laboratory, Leiden, The Netherlands
› Author Affiliations
Further Information

Publication History

Received 31 January 1992

Accepted after revision 30 March 1992

Publication Date:
04 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Soluble fibrin is considered as a molecular marker for intravascular fibrin formation, and impending thrombotic events. Most of the existing assays are less suitable for routine clinical applications and their specificity may be limited.

We have developed a sandwich-type EIA with a fibrin-specific MoAb described by us before (Proc Natl Acad Sci 1989; 86: 8951) as the capture antibody. An other MoAb (G8; Thromb Haemostas 1988; 60: 415) with an epitope in the carboxyl-terminal sections of the fibrin α-chains, was labeled with peroxidase and used as the tagging antibody. The EIA is calibrated against plasma spiked with known concentrations of soluble fibrin. The time-to-result of the EIA is only 1.5 h. Concentrations as low as 0.5 µg soluble fibrin/ml plasma are readily measurable. Heparin has no effect on the results. Fibrinogen and fibrin(ogen) degradation products are not detected. The values of fibrinopeptide A and soluble fibrin values found with the “COA-SET soluble fibrin” assay correlated well with the soluble fibrin values found with our EIA i.e. r = 0.998 and 0.984, respectively. The run-to-run variabilities were 7.9% and 6.6% for samples with low and high soluble fibrin concentrations, respectively. The within-run variabilities were 2.5, 1.8, 4.0 and 4.6% for samples with 1, 0.5, 0.25 and 0.125 µg soluble fibrin/ml, respectively.

The sensitivity, specificity, accuracy and short time-to-result make our EIA suitable for routine clinical applications and the monitoring of the effectivity of heparinization.

 

  • References

  • 1 Nieuwenhuizen W. The use of monoclonal antibodies in demonstrating different fibrinogen derivatives. In: Müller-Berghaus G, Scheefers-Borchel U, Selmayer E, Henschen A. (eds) Excerpta Medica: Amsterdam: 1986. pp 245-246
    Google Scholar
  • 2 Nieuwenhuizen W. Plasma assays of fibrinogen/fibrin degradation products and their clinical relevance. Fibrinogen 2. Biochemistry, Physiology and Clinical Relevance Lowe GDO, Douglas JT, Forbes CD, Henschen A. Excerpta Medica, Amsterdam: 1987: 173-80
    Google Scholar
  • 3 Nieuwenhuizen W. New strategies in the determination of fibrin and fibrin(ogen) derivatives by monoclonal antibodies. Blut 1988; 57: 285-291
    CrossrefPubMedGoogle Scholar
  • 4 Doolittle RF. Structural aspects of the fibrinogen to fibrin conversion. Adv Protein Chem 1973; 27: 1-109
    CrossrefPubMedGoogle Scholar
  • 5 Doolittle RF. Fibrinogen and fibrin. Sci Am 1981; 245: 092-101
    PubMedGoogle Scholar
  • 6 Shainoff JR, Page JH. Significance of cryoprofibrin in fibrinogen-fibrin conversions. J Exp Med 1962; 116: 687-707
    CrossrefPubMedGoogle Scholar
  • 7 Brass EP, Forman WB, Edwards RV, Lindan O. Fibrin formation: The role of the fibrinogen-fibrin complexes. Thromb Haemostas 1976; 36: 36-48
    PubMedGoogle Scholar
  • 8 Graeff H, Hafter R, Von Hugo R. On soluble fibrinogen-fibrin complexes. Thromb Res 1979; 16: 575-576
    CrossrefPubMedGoogle Scholar
  • 9 Hermans J, McDonagh J. Fibrin: Structure and interactions. Semin Thromb Hemostas 1982; 8: 11-24
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Bick RL. Disseminated intravascular coagulation: A clinical/laboratory study of 48 patients. Ann N Y Acad Sci 1981; 370: 843-855
    CrossrefPubMedGoogle Scholar
  • 11 Siegal T, Seligsohn U, Aghai E, Modan M. Clinical and laboratory aspects of disseminated intravascular coagulation (DIC): A study of 118 cases. Thromb Haemostas 1978; 39: 122-140
    PubMedGoogle Scholar
  • 12 Colman RW, Robboy SJ, Minna JD. Disseminated intravascular coagulation (DIC): An approach. Am Rev Med 1972; 52: 679-689
    CrossrefPubMedGoogle Scholar
  • 13 Thomas DP, Niewiarowski S, Myers AR, Block KJ, Colman RW. A comparative study of four methods for detecting fibrinogen degradation products in patients with various diseases. N Engl J Med 1970; 238: 663-668
    PubMedGoogle Scholar
  • 14 Spero JA, Lewis JH, Hasiba U. Disseminated intravascular coagulation: Findings in 346 patients. Thromb Haemostas 1980; 38: 28-33
    PubMedGoogle Scholar
  • 15 Okajima K, Koga S, Okabe H, Inoue M, Takatsuki K. Characterization of the fibrinolytic state by measuring stable cross-linked fibrin degradation products in disseminated intravascular coagulation associated with acute promyelocytic leukemia. Acta Haematol 1989; 81: 15-18
    CrossrefPubMedGoogle Scholar
  • 16 Fruchtman S, Aledort LM. Disseminated intravascular coagulation. J Am Coll Cardiol 1986; 8: 159-167
    CrossrefPubMedGoogle Scholar
  • 17 Breen FA, Tullis JL. Ethanol gelation: A rapid screening test for intravascular coagulation. Ann Intern Med 1968; 69: 1197-1206
    CrossrefPubMedGoogle Scholar
  • 18 Godal HC, Abildgaard U. Gelation of soluble fibrin in plasma by ethanol. Scand J Haematol 1966; 3: 342-350
    PubMedGoogle Scholar
  • 19 Gurewich V, Hutchinson E. Detection of intravascular coagulation by a serial dilution protamine sulfate test. Ann Intern Med 1971; 75: 895-905
    CrossrefPubMedGoogle Scholar
  • 20 Niewiarowski S, Gurewich V. Laboratory identification of intravascular coagulation: The serial dilution protamine sulfate test for the detection of fibrin monomer and fibrin degradation products. J Lab Clin Med 1971; 77: 665-676
    PubMedGoogle Scholar
  • 21 Watanabe K, Tullis JL. Precipitation of fibrin monomers and fibrin degradation products by ristocetin. Am J Med Sci 1978; 275: 337-344
    CrossrefPubMedGoogle Scholar
  • 22 Watanabe K, Tullis JL. Ristocetin precipitation test: A new simple test for the detection of fibrin monomer and fibrin degradation products. Am J Clin Pathol 1978; 70: 691-696
    CrossrefPubMedGoogle Scholar
  • 23 Largo R, Heller V, Straub PW. Detection of soluble intermediates of the fibrinogen-fibrin conversion using erythrocytes coated with fibrin monomers. Blood 1976; 47: 0991-1002
    PubMedGoogle Scholar
  • 24 Fletcher AP, Alkjaersig N, O’Brien J, Tulevski VG. Blood hypercoagulability and thrombosis. Transact Assoc Am Physicians 1970; 83: 159-167
    PubMedGoogle Scholar
  • 25 Graeff H, von Hugo R. Identification of fibrinogen derivatives in plasma samples. Thromb Diath Haemorrh 1972; 27: 610-618
    PubMedGoogle Scholar
  • 26 Heene DL, Matthias FR. Adsorption of fibrinogen derivatives on insolubilized fibrinogen and fibrin monomer. Thromb Res 1973; 2: 137-154
    CrossrefPubMedGoogle Scholar
  • 27 Matthias FR, Reinicke R, Heene DL. Affinity chromatography and quantification of soluble fibrin from plasma. Thromb Res 1977; 10: 365-384
    CrossrefPubMedGoogle Scholar
  • 28 Wiman B, Rånby M. Determination of soluble fibrin in plasma by a rapid and quantitative spectrophotometric assay. Thromb Haemostas 1986; 55: 189-193
    PubMedGoogle Scholar
  • 29 Scheefers-Borchel U, Müller-Berghaus G, Fuhge P, Eberle R, Heimburger N. Discrimination between fibrin and fibrinogen by a monoclonal antibody against a synthetic peptide. Proc Natl Acad Sci USA 1985; 82: 7091-7095
    CrossrefPubMedGoogle Scholar
  • 30 Schielen WJG, Voskuilen M, Tesser GI, Nieuwenhuizen W. The sequence Aα-[148–160] in fibrin, but not in fibrinogen, is accessible to monoclonal antibodies. Proc Natl Acad Sci USA 1989; 86: 8951-8954
    CrossrefPubMedGoogle Scholar
  • 31 Hoegee-De Nobel E, Voskuilen M, Briët E, Brommer EJP, Nieuwenhuizen W. A monoclonal antibody-based quantitative enzyme immunoassay for the determination of plasma fibrinogen concentrations. Thromb Haemostas 1988; 60: 415-418
    PubMedGoogle Scholar
  • 32 Bouvet JP, Pires R, Pillot J. A modified gel filtration technique producing an unusual exclusion volume of IgM: a simple way of preparing monoclonal IgM. J Immunol Meth 1984; 66: 299-305
    CrossrefPubMedGoogle Scholar
  • 33 Ey PL, Prowse SJ, Jenkin CR. Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A Sepharose. Immunochemistry 1978; 15: 429-436
    CrossrefPubMedGoogle Scholar
  • 34 Carlsson J, Orevin H, Axén R. Protein thiolation and reversible protein-protein conjugation. N-Succinimidyl 3-(2-pyridyldithio) propionate: a new heterobifunctional reagent. Biochem J 1978; 173: 723-737
    PubMedGoogle Scholar
  • 35 Nieuwenhuizen W, Creighton LC, Gaffney PJ, Graeff H, Hafter R, Hoegee-De Nobel E, Müller-Berghaus G, Scheefers-Borchel U, Thurmayer R, Davies JA, Duckert F, Jespersen J, Matthias FR, Prentice CRM, Preston FE, Samama MM. A double blind comparative study of six monoclonal antibody-based plasma assay for fibrinogen derivatives. Fibrinogen 2. Biochemistry Physiology and Clinical Relevance Lowe GDO, Douglas JT, Forbes CD, Henschen A. Excerpta Medica, Amsterdam: 1987: 181-188
    Google Scholar
  • 36 Koopman J, Haverkate F, Koppert P, Nieuwenhuizen W, Brommer EJP, Van der Werf WGC. New enzyme immunoassay of fibrinfibrinogen degradation products in plasma using a monoclonal antibody. J Lab Clin Med 1987; 109: 75-84
    PubMedGoogle Scholar